Navigation Links
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
Date:6/5/2009

portant implications for our ability to develop an effective treatment for swine flu and other H1N1 flu viruses."

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include: an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Isis and Collaborators Present New Research at the ATVB Annual Conference
2. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
3. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
6. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
9. MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
10. PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... TEL AVIV, Israel , March 30, 2015   ... , announced the closing of $12.5 million in new financing ... the Viola Group. The funding will further GlassesUSA,s aggressive business ... the growing global market of online eyewear, both B2C and ... Daniel Rothman , COO Eldad Rothman , and ...
(Date:3/30/2015)... 2015  Zimmer Holdings, Inc. (NYSE and SIX: ... ("EC") has conditionally cleared Zimmer,s proposed acquisition of ... upon Zimmer entering into agreements with a suitable ... package previously submitted to the EC.  Zimmer expects ... term.  As previously announced, the proposed transaction also ...
(Date:3/30/2015)... , March 30, 2015  The future ... to involve more data analytics; new, more precise ... imaging and motion management techniques.  Some 150 researchers ... ideas last week at a symposium on research ... ).     "Researchers are developing, testing, ...
Breaking Medicine Technology:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 2Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 4Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 5Radiation Oncology Researchers Glimpse the Future of Cancer Care 2Radiation Oncology Researchers Glimpse the Future of Cancer Care 3Radiation Oncology Researchers Glimpse the Future of Cancer Care 4Radiation Oncology Researchers Glimpse the Future of Cancer Care 5Radiation Oncology Researchers Glimpse the Future of Cancer Care 6
(Date:3/30/2015)... Jose, California (PRWEB) March 30, 2015 ... Defined as radioactive isotopes, radiopharmaceuticals are used as ... The global market for radiopharmaceuticals is driven by ... procedures in the field of cardiology, neurology, pulmonology, ... supported by the well-established use of radioisotopes in ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 South Coast Surety ... a Surety Bond Representative. Richard has been known to the ... decade. , Richard attended the University of Georgia, majoring in ... decades in the sales and sales management of business equipment ... , Most recently, Richard was a senior officer with ...
(Date:3/30/2015)... DC (PRWEB) March 30, 2015 Daily ... toll on the face, causing wrinkles, folds and other ... invasive techniques empower men and women to hit the ... time. Today, there’s a nip, tuck or hack to ... of Facial Plastic and Reconstructive Surgery (AAFPRS) explores ...
(Date:3/30/2015)... States (PRWEB) March 30, 2015 Poo puts ... anything that could be better than Paleo, or better than ... out Poo - just released on the app store! ... step counting, there is a whole other half to that ... , With Poo, users do the dirty work, and then ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Mid-America ... mobile library of medications used in behavioral health ... iPhone, iPad and Android—is a convenient, electronic version ... since 1999. The useful resource provides up-to-date information ... dosage and frequency, side effects, emergency conditions, cautions, ...
Breaking Medicine News(10 mins):Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:Richard Ford Joins South Coast Surety Contract Surety Team 2Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Popular Publication on Behavioral Health Medications Now An App 2
... (BPA) -- a substance that may have harmful health ... register receipts, scientists are reporting. The recycling of those ... of paper napkins, toilet paper, food packaging and other ... for cashiers and other people who routinely handle thermal ...
... a major earthquake experienced high levels of post-traumatic stress disorder ... affected, according to a study published in the November issue ... led by the West China School of Nursing and West ... 12 to 20 years of age three months after the ...
... a biochemist at the University of the Basque Country (UPV/EHU), ... term, the early diagnosis of cancer of the large intestine ... known as peptidases and their activity (working rate): she has ... at different stages of the disease. If these fluctuations could ...
... , WEDNESDAY, Oct. 26 (HealthDay News) -- People ... attempt to boost their social status, a new study suggests. ... portions with higher social standing. For example, study participants believed ... social status than those who chose a medium or small ...
... -- A new potential leukemia therapy targets only cancer ... chemotherapy treatments affect cancer cells and healthy cells, causing ... anxiety and depression. This research is being presented ... Annual Meeting and Exposition in Washington, D.C., Oct. 23 ...
... It is known that a high proportion of dense breast ... high risk of breast cancer. But the role of non-dense ... published in BioMed Central,s open access journal Breast Cancer ... fibroglandular tissue, and fat, and shows that large areas of ...
Cached Medicine News:Health News:Teenage girls and senior students suffered highest levels of PTSD after major earthquake 2Health News:Teenage girls and senior students suffered highest levels of PTSD after major earthquake 3Health News:Steps being taken towards achieving an early diagnosis of cancer of the large intestine 2Health News:Steps being taken towards achieving an early diagnosis of cancer of the large intestine 3Health News:Larger Food Portions May Be Seen as Status Symbols 2
The Streck-MD-Pack is specially designed for use on Coulter® MD Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Medicine Products: